Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab

Adalimumab is a fully humanized anti-tumor necrosis factor alpha monoclonal antibody that was recently granted regulatory approval in the USA for the treatment of moderate to severe Crohn’s disease (CD) in children. Like infliximab, the first biologic agent used to treat pediatric CD, regulatory app...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeisler, Bella, Hyams, Jeffrey S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683269/
https://www.ncbi.nlm.nih.gov/pubmed/29388607
http://dx.doi.org/10.2147/PHMT.S40948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683269/
https://www.ncbi.nlm.nih.gov/pubmed/29388607
http://dx.doi.org/10.2147/PHMT.S40948

Ejemplares similares